← Human Trials & Peer-Reviewed Studies
Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue
Plain-language guide to PMID 20103448 (2010): randomized controlled trial study of Leuprolide in 44 patients, endometriosis.
Key Facts
- PMID
- 20103448
- Journal
- Contraception
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Ferreira RA et al. (6 authors)
- DOI
- 10.1016/j.contraception.2009.08.003
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Leuprolide in the context of endometriosis, published as a randomized controlled trial.
Who Took Part
According to the abstract, 44 patients were involved.
By PubMed's age tags, the people studied were adults, women only.
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The methods mention a period of 6 months.
Body mass index; systolic and diastolic arterial blood pressure; heart rate; and laboratory cardiovascular risk markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), homocysteine (HMC), lipid profile, total leukocytes and vascular cell adhesion molecule (VCAM) were measured before and 6 months after treatment.
What Was Measured
Topics PubMed links to this paper include Biomarkers, Cardiovascular System, Contraceptive Agents, Female, Endometriosis, Homocysteine, Interleukin-6 and Intrauterine Devices, Medicated.
What This Means in Plain Language
The paper is a randomized study of Leuprolide in 44 patients in people with endometriosis over 6 months.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (Contraception), a journal based in United States.
More context: the Leuprolide compound page, Endometriosis research.
Our Notes on the Compound
Leuprolide: A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.